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ABSTRACT
OBJECTIVES
To assess function, quality of life, resource use, and 
complications in adults treated with plaster cast 
immobilisation versus a removable brace for ankle 
fracture.
DESIGN
Multicentre randomised controlled trial.
SETTING
20 trauma units in the UK National Health Service.
PARTICIPANTS
669 adults aged 18 years and older with an acute 
ankle fracture suitable for cast immobilisation: 334 
were randomised to a plaster cast and 335 to a 
removable brace.
INTERVENTIONS
A below the knee cast was applied and ankle range 
of movement exercises started on cast removal. 
The removable brace was fitted, and ankle range of 
movement exercises were started immediately.
MAIN OUTCOME MEASURES
Primary outcome was the Olerud Molander ankle 
score at 16 weeks, analysed by intention to treat. 
Secondary outcomes were Manchester-Oxford foot 
questionnaire, disability rating index, quality of life, 
and complications at 6, 10, and 16 weeks.
RESULTS
The mean age of participants was 46 years (SD 17 
years) and 381 (57%) were women. 502 (75%) 
participants completed the study. No statistically 
significant difference was found in the Olerud 
Molander ankle score between the cast and 
removable brace groups at 16 weeks (favours 
brace: 1.8, 95% confidence interval −2.0 to 5.6). No 
clinically significant differences were found in the 
Olerud Molander ankle scores at other time points, in 
the secondary unadjusted, imputed, or per protocol 
analyses.
CONCLUSIONS
Traditional plaster casting was not found to be 
superior to functional bracing in adults with an ankle 
fracture. No statistically difference was found in the 





Each year more than 120 000 people in the United 
Kingdom experience an ankle fracture.1 Such fractures 
represent a major trauma workload, and demand is 
increasing—because the number of older adults who 
remain active is increasing, by 2030 ankle fractures 
are expected to increase threefold.1 2 The frequency 
of this injury places an increasing burden on the UK 
National Health Service.3 Affected adults are unable 
to engage in usual physical activities for prolonged 
periods.1 2 4 The qualitative impact on individuals is 
substantial, affecting family and social life, sleep, 
sense of independence, and psychological wellbeing.5
Conventionally, after fracture the ankle is 
immobilised in a rigid cast for several weeks, which 
allows the bones to heal but can result in joint 
stiffness and muscle weakness.6 An alternative is a 
removable brace, which can be taken off to allow early 
movement. Using a removable brace could prevent 
the consequences of rigid immobilisation and help to 
accelerate recovery. Both methods are routinely used 
in the UK.
A Cochrane review concluded that functional 
bracing might reduce activity limitation and pain and 
improve ankle movement. These potential advantages, 
however, need to be balanced against the increased 
incidence of adverse events. High quality evidence is 
not available to support the effectiveness or safety of 
early movement after ankle fracture.6
In light of the increasing numbers of ankle fractures 
and large personal and societal costs, we compared 
removable bracing with casting on function, quality of 
life, and complications in adults with an ankle fracture.
Methods
This pragmatic, multicentre, superiority randomised 
controlled trial was undertaken at 20 trauma units in 
the UK National Health Service. The trial protocol (see 
supplementary file 1) was accepted for publication 
on 31 October 2018 and first published online on 
18 December 2018.7 The independent trial steering 
committee and data and safety monitoring committee 
approved the statistical analysis plan. These 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Management of a fractured ankle has traditionally included cast immobilisation, 
which provides maximum support to bones during healing
As rigid immobilisation in a cast can result in stiff joints and weakened muscles, 
removable bracing might help with these problems by allowing earlier movement
It is not known which of these treatments is superior
WHAT THIS STUDY ADDS
Plaster cast immobilisation was not found to be superior to functional bracing for 
ankle fractures in adults at 16 weeks
Other factors will need to be considered in deciding optimal management 










J: first published as 10.1136/bm





2 doi: 10.1136/bmj.n1506 | BMJ 2021;374:n1506 | the bmj
independent committees were convened to oversee the 
study throughout the trial’s duration.
Participants
Trauma research teams at UK NHS trust sites screened 
adults aged 18 years and older with a closed ankle 
fracture. In this pragmatic study design, if the treating 
clinician would usually treat the fracture in a cast 
for a minimum of three weeks, whether treated non-
operatively or operatively, then the patient was 
considered eligible. Therefore, patients did not meet 
the initial criteria for entry to the study if the clinician 
decided that no immobilisation (cast or brace) was 
required.
On further screening, people were excluded if 
they had a fracture secondary to known metastatic 
disease, complex intra-articular fracture (eg, Pilon 
fracture), wound complications contraindicating a 
removable bracing, pre-existing neuropathic joint 
disease, previous ankle fracture already randomised 
in the present trial, were unable to adhere to trial 
follow-up procedures, or required close contact 
casting.8
Indications for first line definitive management 
(operative or non-operative) were according to 
usual practice for each individual clinician, as were 
any adjunctive treatments (eg, antibiotic use). The 
trial population included patients managed both 
operatively and non-operatively.
Operatively managed participants had initially 
received standard local clinical care in the UK, typically 
consisting of a temporary partial backslab, and wound 
check about two weeks after surgery. At this point 
in the care pathway, randomisation processes were 
completed and a member of the clinical team applied 
the intervention.
Non-operatively managed participants completed 
the randomisation processes immediately at 
presentation to the trauma service, when a member of 
the clinical team then applied the cast or removable 
brace. As it is usual clinical practice in the UK to delay 
decisions about first line non-operative management 
(ie, to check if the fracture is stable) for some patients, 
our eligibility criteria allowed up to three weeks before 
a definitive decision was required.
Randomisation and blinding
Baseline data were collected before randomisation. 
Participants were randomised on a 1:1 basis to the 
two study intervention arms sequentially as they 
presented. A secure web based system maintained 
by an independent randomisation team allocated 
participants using a minimisation algorithm with a 
random element and stratification by centre, operative 
or non-operative management, and age (≤49 v ≥50 
years).1 9
Blinding of participants and clinicians was not 
possible. All follow-up data were participant reported 
through postal questionnaires; no clinicians or 
researchers assessed outcome measures.
Interventions
The interventions were worn for a minimum of three 
weeks in both groups.
Standard below knee cast immobilisation was 
applied according to local procedures. Participants in 
the cast group started active unloaded ankle range of 
movement exercises once the cast was removed.
Removable braces were of a fixed angle design, to 
replicate what is routinely used in UK practice, and 
were applied in accordance with local procedures. 
The specific brand of removable brace was not 
standardised across sites, and each site used its own 
brand. The treating clinician in the trauma service 
setting encouraged participants in verbal and written 
formats to take off the removable brace to complete 
active unloaded ankle range of movement exercises as 
often as pain allowed, with a recommendation for each 
movement to be performed 10 times, three times a day 
(see supplementary file 2).
In this pragmatic trial, any other rehabilitation input 
beyond rigid immobilisation in a cast compared with 
early active movement in a removable brace was at the 
discretion of the treating member of the clinical team, 
in accordance with current UK practice. This included 
choice of weightbearing for the participant, duration of 
immobilisation period (beyond the minimum of three 
weeks), and decision to onward refer participants to 
physiotherapy services. These details were collected 
for each participant as part of the trial dataset.
Outcome measures
The primary outcome was the Olerud Molander ankle 
score at 16 weeks; a self-administered questionnaire 
that consists of nine different items (pain, stiffness, 
swelling, stair climbing, running, jumping, squatting, 
supports, and work or activities of daily living).10 
Scores range from 0 for totally impaired to 100 for 
completely unimpaired.
We chose the primary outcome time point of 16 
weeks after consultation with academics, clinicians, 
and public and patient representatives. This time 
point was based on previous trials of ankle fracture, 
which found that the steepest recovery occurs in the 
first four months of injury.8 Additional longer term 
secondary data are being collected at 6, 12, 18, and 
24 months as part of a preplanned longer term follow 
up, to be reported separately to capture any later stage 
complications.
Secondary outcomes were complications (deep vein 
thrombosis, pulmonary embolism, pain, swelling, 
numbness around the foot, wound infection, and 
fracture healing), resource use, and self-administered 
health related quality of life measures (EQ-5D-5L) and 
leg specific functional scores (Manchester-Oxford foot 
questionnaire and disability rating index).11-13 All data 
were collected at 6, 10, and 16 weeks, except for the 
Manchester-Oxford foot questionnaire, which was 
collected at 16 weeks only. All follow-up data were 
collected through postal questionnaires returned to 
the central trial team.
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Statistical analysis
The target between group difference for the primary 
Olerud Molander ankle score outcome was 10 points, 
consistent with other studies of ankle fracture 
management—this is the accepted minimally clinically 
important difference.8 14 The standard deviation of the 
Olerud Molander ankle score from previous feasibility 
work was 28 points, so we used a conservative estimate 
of 30 points for the sample size calculation.15 With 
significance set at the 5% level and at 90% power, we 
determined that we needed data on 382 participants. 
Allowing for 20% loss to follow up, 478 participants 
were required. As recruitment exceeded planned 
expectations, to improve precision of our effect size 
estimate we obtained relevant approvals to continue 
recruiting to the predefined end recruitment date. The 
study was not powered to detect differences in the 
secondary outcome measures.
The primary analysis was the Olerud Molander ankle 
score at 16 weeks. The planned main analysis, which 
was on an intention-to-treat basis, used adjusted mixed 
effects linear regression analysis to assess evidence for 
differences in the Olerud Molander ankle score between 
the intervention arms. We included study recruitment 
centre as a random effect and adjusted the analysis for 
the stratification variables (age and operative or non-
operative management) as fixed effects. Participants 
who maintained their allocated intervention for at 
least three weeks were considered to have followed the 
protocol. A sensitivity analysis to investigate the effect 
of missingness and adherence was conducted using 
multiple imputation.16 All analyses were implemented 
in R.17
Two prespecified subgroup analyses were 
undertaken to determine whether the intervention 
effect differed between participants who received 
operative or non-operative treatment before the study 
intervention and between those who were younger 
than 50 years or 50 years and older at randomisation; 
those older than 50 years being more likely to have 
experienced a fragility fracture related to osteoporosis. 
The original cut-off for 60 years was amended to 50 
years following advice from the independent oversight 
committees but before publication of the final protocol7 
and approval of the statistical analysis plan. The 
subgroup analyses followed the methods described for 
the primary analysis, with additional interaction terms 
incorporated into the mixed effects model.
Patient and public involvement
Public and patient representatives co-produced 
this study. After a single site feasibility trial funded 
by the National Institute for Health Research 
(ISRCTN17809322),15 two public and patient 
representatives (RG and KK) continued their roles 
through the planning, development, and delivery of 
the current main randomised controlled trial.
Results
Between 9 October 2017 and 30 September 2019, 
20 NHS trusts screened 3144 adults with an ankle 
fracture, of whom 1152 were not eligible. Of the 
remaining 1992 (35%) participants, 669 were 
randomised: 334 to a cast and 335 to a removable 
brace. Six hundred and twenty seven of the remaining 
1323 patients (31%) did not want to take part in the 
trial (428 had preference for a specific treatment, 79 
did not want to be part of a research study, and 90 had 
other reasons) and for the other 696 (35%) patients 
the treating clinician did not offer the option to take 
part (579 had preference for a specific treatment and 
117 had other reasons).
Twenty seven participants withdrew before the 
primary outcome point of 16 weeks. Five hundred 
and two participants completed the primary outcome 
Olerud Molander ankle score score (75%) and were 
included in the final analysis (fig 1).
The mean age of participants was 46.3 years (SD 17 
years) and more than half the participants were women 
(57%). All participants had a clear ankle fracture 
on a radiograph, with 624 (93%) showing lateral 
malleolar involvement, 194 (29%) medial malleolar 
involvement, and 120 (18%) posterior malleolar 
involvement. Ankle fracture in 428 (64%) participants 
was due to a low energy fall. Surgery was performed 
in 54% of the randomised participants. The groups 
were well balanced across all baseline characteristics 
(table 1).
Twenty three participants in the cast group 
(n=334) did not adhere to the treatment allocation 
and crossed over to the removable brace group (20 
owing to participant preference). Seven participants 
in the removable brace group (n=335) did not adhere 
to the treatment allocation and crossed over to the 
cast group (four owing to participant preference; see 
supplementary file 3, table 4).
Other rehabilitation input beyond rigid 
immobilisation in a cast versus early active movement 
in a removable brace was at the discretion of the treating 
member of the clinical team. This input was balanced 
across the groups. The number of onward referrals to 
physiotherapy was similar between the groups: 182 in 
the cast group and 166 in the removable brace group 
(see supplementary file 3).
No statistically significant difference was found in 
the Olerud Molander ankle score at 16 weeks, using 
the primary adjusted intention-to-treat analysis (mean 
difference 1.8, 95% confidence interval −2.0 to 5.6, 
favours brace). Nor was a clinically relevant difference 
found at the six week and 10 week time points (table 
2). No clinically relevant differences were found in 
the disability rating index, Manchester-Oxford foot 
questionnaire, or EQ-5D-5L secondary outcomes at 
any time point (table 3). 
The results of secondary unadjusted and per protocol 
analyses were not materially different from those of 
the primary analysis. The study was not, however, 
powered to detect a difference in secondary outcome 
data. No evidence was found in predefined subgroup 
analyses that effects differed according to age or 
whether or not the participant had surgical treatment 
(see supplementary file 3, table 6).
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As loss to follow-up was higher than the expected 
20% at the primary analysis point, multiple imputation 
using chain equations was used to investigate the 
robustness of the results. Missingness of the primary 
outcome was not evenly distributed between the 
groups, with more data missing in the cast group 
(completeness: cast group 73%; removable brace 
78%).
Twenty five imputed datasets were created for each 
model and the coefficients were pooled using Rubin’s 
rules used to combine estimates. Missing data on the 
Olerud Molander ankle score were imputed using a 
predictive mean matching method. Variables were 
chosen from the baseline and randomisation set on 
the basis of association with missingness at 16 week 
follow-up. Predictor variables chosen were fractures 
on medial and posterior malleolus, concurrent injuries 
on the same leg, body weight, smoking status, age 
group, sex, and fracture management.
Sensitivity analyses on the imputed dataset gave 
similar results to those of the primary analysis, 
suggesting that missingness did not impact on 
the interpretation of the primary analysis (see 
supplementary file 3, table 3).
Complications were similar across the two groups. 
Important complications in the cast group were 
deep vein thrombosis (n=3), pulmonary embolism 
(n=1), chronic regional pain syndromes (n=2), and 
further surgery (n=4)—revision surgery for failed 
primary fixation (n=1), elective removal of metal 
work (n=2), and removal of metal work secondary 
to infection (n=1). Important complications in the 
Patients referred to trauma or orthopaedic clinic with ankle fracture
Eligibility criteria not met
Beyond 3 weeks of operative management, or injury if non-operative
Ankle fracture secondary to known metastatic disease
Complex, intra-articular fracture
Manipulation and close contact cast required
Manipulation and moulded cast required
Wound complication contraindicated functional brace
Patient previously randomised in present trial
Patient unable to adhere to trial procedures



























Allocated to plaster cast Allocated to removable brace
3144
Patients referred to trauma or orthopaedic clinic with ankle fracture
1992
1152
Patients eligible but not randomised 





Included in primary analysis Included in primary analysis
260242
Missing from primary analysis Missing from primary analysis
Completed baseline Completed baseline
332327
92 75
Withdrew16 Missing76 Withdrew11 Missing64
Fig 1 | Trial profile
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removable brace group were deep vein thrombosis 
(n=3), pulmonary embolism (n=1), chronic regional 
pain syndrome (n=1), problems with fracture healing 
(n=1), and further surgery (n=8)—revision surgery for 
failed primary fixation (n=1), elective removal of metal 
work (n=4), and removal of metal work secondary to 
infection (n=3; table 4).
Discussion
This randomised controlled trial found no statically 
significant difference in ankle function between a plaster 
cast and a removable fixed angle brace at 16 weeks in 
adults with an ankle fracture. The upper limit of the 95% 
confidence interval effectively excluded any possibility 
that one intervention was superior to the other.
Table 1 | Baseline characteristics of adults with ankle fracture allocated to plaster cast or removable brace in intention-
to-treat population*
Characteristics Cast (n=334) Removable brace (n=335) Overall (n=669)
Sex:
 Women 198 (59) 183 (55) 381 (57)
 Men 136 (41) 152 (45) 288 (43)
Ethnicity:
 Asian 15 (5) 12 (4) 27 (4)
 Black, African, and Caribbean 15 (5) 14 (4) 29 (4)
 Mixed race 7 (2) 8 (2) 15 (2)
 Other 47(2) 6 (2) 13 (2)
 White 289 (87) 289 (88) 581 (87)
Mean (SD) pre-injury OMAS score 93.4 (16) 93.4 (16) 93.4 (16)
Mean (SD) baseline (post-injury) OMAS score 20.8 (17) 21.2 (18) 21.0 (17)
Mean (SD) age (years) 46.7 (17) 45.9 (16) 46.3 (17)
Age category (years):
 ≤49 185 (55) 186 (56) 371 (55)
 ≥50 149 (45) 149 (44) 298 (45)
Mean (SD) body mass index 28.2 (6) 28.6 (6) 28.4 (6)
Mechanism of injury†:
 Low energy fall 216 (64) 212 (63) 428 (64)
 High energy fall 49 (15) 60 (18) 109 (16)
 Road traffic incident 14 (4) 12 (4) 26 (4)
 Crush injury 1 (<1) 1 (<1) 2 (<1)
 Sports injury 26 (8) 23 (7) 49 (7)
 Other 32 (10) 29 (8) 61 (9)
Side of injury:
 Right 158 (47) 170 (51) 328 (49)
 Left 176 (52) 161 (48) 337 (50)
Malleolus involvement†:
 Lateral 310 (93) 314 (94) 624 (93)
 Medial 110 (33) 84 (25) 194 (29)
 Posterior 60 (18) 60 (18) 120 (18)
Fracture management:
 Operative 182 (55) 182 (54) 364 (54)
 Non-operative 152 (45) 153 (46) 305 (46)
Advised weightbearing:
 Full 110 (33) 109 (33) 219 (33)
 Partial 65 (20) 75 (22) 140 (21)
 None 157 (47) 146 (44) 303 (45)
Concurrent injuries:
 No 307 (92) 317 (95) 624 (93)
 Yes 27 (8) 18 (5) 45 (7)
Regular smoker:
 No 268 (80) 259 (77) 527 (79)
 Yes 64 (19) 71 (21) 135 (20)
Alcohol/week (units):
 0-7 233 (70) 205 (61) 438 (65)
 8-14 50 (15) 71 (21) 121 (18)
 15-21 31 (9) 33 (10) 64 (10)
 >21 20 (6) 24 (7) 44 (7)
Concurrent drugs:
 Steroids 14 (4) 10 (3) 24 (4)
 Other 224 (67) 215 (64) 439 (66)
Diagnosis before injury:
 Diabetes 16 (5) 16 (5) 32 (5)
 Leg fracture (past 12 months) 3 (1) 2 (1) 5 (1)
 Injury to leg (past 12 months) 2 (1) 4 (1) 6 (1)
OMAS=Olerud Molander ankle score.
*<3% missing in any category.
†Multiple categories possible.










J: first published as 10.1136/bm





6 doi: 10.1136/bmj.n1506 | BMJ 2021;374:n1506 | the bmj
No clinically relevant differences were found in 
Olerud Molander ankle score at secondary time points 
or in the secondary outcome measures of Manchester-
Oxford foot questionnaire, disability rating index, 
quality of life, and complications. We found no 
statistically significant differences in the safety profiles 
of serious complications across both interventions. 
A higher number of complications occurred in the 
removable brace group, particularly wound breakdown 
(7 v 15), wound infection (10 v 19), and need for further 
surgery (4 v 8).The study was not, however, powered to 
detect a difference in these secondary outcomes.
Comparison with other studies
A Cochrane review identified 10 randomised 
controlled trials that compared a removable type 
of immobilisation and early movement with a cast 
and no early movement (n=531).6 In our updated 
search, we identified four subsequent randomised 
controlled trials (n=451).14 15 18 19 One trial (n=50) 
was the Ankle Injury Rehabilitation feasibility 
study to this current study and made no inferences 
to clinical effectiveness.15 A further study (n=110) 
concluded that removable bracing was superior at 
six weeks, but the difference on the Olerud Molander 
ankle score diminished by 12 weeks.18 These findings 
were supported by a further randomised controlled 
trial that used a visual analogue scale pain score as 
a primary measure (n=44).14 The largest randomised 
controlled trial (n=247) indicated non-inferiority 
of removable bracing at 6, 12, and 52 weeks using 
the Olerud Molander ankle score.19 No trials found 
a difference in safety profiles of removable bracing 
compared with cast.
This trial did not find any clinically relevant 
differences between traditional cast compared with 
Table 2 | Olerud Molander ankle score (OMAS) in adults with ankle fracture allocated to plaster cast or removable brace 
in intention-to-treat population*
Cast (n=334) Removable brace (n=335) Between group difference (95% CI)
No Mean (SD) OMAS No Mean (SD) OMAS Unadjusted Adjusted† P value
6 weeks 241 37.2 (22.1 256 39.6 (20.6) 2.4 (−1.4 to 6.2) 2.2 (−1.4 to 5.8) 0.23
10 weeks 229 47.1 (21.7) 239 51.5 (23.0) 4.5 (0.4 to 8.5) 4.5 (0.6 to 8.3) 0.02
16 weeks 242 62.4 (23.4) 260 64.5 (22.4) 2.1 (−1.9 to 6.2) 1.8 (−2.0 to 5.6) 0.35
*Positive values in favour of removable brace.
†Estimates are from linear regression model adjusted for patient sex, age group, and fracture management at baseline.
Table 3 | Secondary outcomes in adults with ankle fracture allocated to plaster cast or removable brace in intention-to-
treat population*
Cast (n=334) Removable brace (n=335) Between group difference (95% CI)
No Mean (SD) No Mean (SD) Unadjusted Adjusted† P value
DRI:
 6 weeks 222 57.7 (20.6) 247 51.7 (22.6) −6.0 (−9.9 to −2.1) −5.6 (−9.4 to −1.8) 0.004
 10 weeks 218 43.8 (22.5) 229 38.8 (23.4) −5.0 (−9.3 to −0.8) −5∙0 (−9.2 to −0.9) 0.01
 16 weeks 213 32.8 (23.9) 235 31.4 (24.7) −1∙5 (−6.0 to 3.0) −1.0 (−5.4 to 3.4) 0.65
EQ-5D-5L:
 6 weeks 241 0.497 (0.272) 258 0.534 (0.258) 0.037 (−0.010 to 0.084) 0.036 (−0.010 to 0.082) 0.12
 10 weeks 228 0.647 (0.192) 239 0.66 (0.18) 0∙013 (−0.021 to 0.047) 0.013 (−0.020 to 0.047) 0.43
 16 weeks 241 0.702 (0.198) 259 0.73 (0.177) 0∙028 (−0.005 to 0.061) 0.026 (−0.006 to 0.058) 0.11
MOXFQ:
 16 weeks 218 38.9 (24.7) 233 36.9 (23.6) −2.0 (−6.5 to 2.5) −1.32 (−5.6 to 3.0) 0.54
DRI=disability rating index; EQ-5D-5L=self-administered health related quality of life measures; MOXFQ=Manchester-Oxford foot questionnaire.
*Positive values in favour of removable brace.
†Fixed effect model accounting for sex, age group, and fracture management only. Random effect model did not improve fit, hence omitted.
Table 4 | Analysis of secondary outcome complications from baseline to 16 weeks in adults with ankle fracture allocated 
to plaster cast or removable brace in intention-to-treat population.* Values are numbers (percentages) unless stated 
otherwise
Cast (n=334) Removable brace (n=335) Odds ratio (95% CI) P value†
Wound infection requiring antibiotics‡ 10 (5.5) 19 (10.4) 2.0 (0.9 to 5.0) 0.12
Wound breakdown or dehiscence‡ 7 (3.8) 15 (8.2) 2.2 (0.8 to 6.7) 0.12
Further surgery for ankle fracture‡ 4 (2.2) 8 (4.4) 1.8 (0.5 to 7.1) 0.41
Pressure sore or ulcer 10 (3.0) 6 (1.8) 0.6 (0.17 to 1.8) 0.32
Numbness at side of foot 51 (15.3) 42 (12.5) 0.8 (0.5 to 1.3) 0.31
Non-union of fracture 0 1 (0.3) NA 1.00
Deep vein thrombosis 3 (0.9) 3 (0.9) 1 (0.1 to 7.5) 1.00
Pulmonary embolism 1 (0.3) 1 (0.3) 1 (0.0 to 78.4) 1.00
Chronic regional pain syndrome 2 (0.6) 2 (0.6) 1 (0.1 to 13.8) 1.00
NA=not applicable.
*Numbers represent complications reported at least once by each participant.
†Fisher’s exact test.
‡Numbers are only applicable to those who had operative management: cast (n=182) removable brace (n=182).
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removable brace management at any time point, in 
keeping with previous trials.
Strengths and limitations of this study
The current trial, a large scale pragmatic randomised 
controlled trial, was designed to evaluate the clinical 
effectiveness of a plaster cast versus removable 
bracing for the management of ankle fractures in 
adults. The main limitation of our study was the 25% 
loss to follow-up; however, the minimum sample 
size was exceeded by a large margin and our post 
hoc sensitivity analysis, accounting for missing data, 
produced similar results to the primary analysis, 
providing reassurance that the primary analysis was 
robust. Bias could potentially have been introduced 
because participants who were lost to follow-up 
might have been different from those included in 
the final analysis, although baseline characteristics 
of the randomised population compared with the 
analysed population were similar, providing further 
reassurance.
Conclusions and policy implications
This trial provides strong evidence for no statistically 
significant difference between traditional cast 
immobilisation and removable bracing for ankle 
fractures in adults. Future research should consider 
the importance of later stage rehabilitation after the 
initial immobilisation phase.
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